{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:01:57Z","timestamp":1789178517694,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejmech.2021.113397","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:51:38Z","timestamp":1617187898000},"page":"113397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Discovery of multifunctional anti-Alzheimer\u2019s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and \u03b3-aminobutyric acid transporters"],"prefix":"10.1016","volume":"218","author":[{"given":"Anna","family":"Pasieka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Panek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jo\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Gody\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sza\u0142aj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mezeiova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Chantegreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damijan","family":"Knez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbiao","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-7596","authenticated-orcid":false,"given":"Jan","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-1032","authenticated-orcid":false,"given":"Xavier","family":"Brazzolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-3083","authenticated-orcid":false,"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"H\u00f6fner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wi\u0119ckowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Malawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113397_bib1","first-page":"759","article-title":"Outcomes of Alzheimer\u2019s disease therapy with acetylcholinesterase inhibitors and memantine","volume":"13","author":"Zemek","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2021.113397_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113397_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu115","article-title":"Combination therapy with cholinesterase inhibitors and memantine for alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"18","author":"Matsunaga","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2021.113397_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/5380346","article-title":"Clinical trials in alzheimer\u2019s disease: a hurdle in the path of remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejmech.2021.113397_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jnc.15023","article-title":"What works and what does not work in Alzheimer\u2019s disease? From interventions on risk factors to anti-amyloid trials","volume":"155","author":"Bullain","year":"2020","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113397_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures","volume":"16","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejmech.2021.113397_bib8","article-title":"World Alzheimer Report 2018 the state of the art of dementia research: new frontiers","author":"Patterson","year":"2018","journal-title":"Alzheimer\u2019s Dis. Int."},{"key":"10.1016\/j.ejmech.2021.113397_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.06.004","article-title":"Alzheimer\u2019s disease due to loss of function: a new synthesis of the available data","volume":"143","author":"Kepp","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113397_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1132814","article-title":"A\u00a0century of Alzheimer\u2019s disease","volume":"314","author":"Goedert","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113397_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000464422","article-title":"Molecular pathogenesis of alzheimer\u2019s disease: an update","volume":"24","author":"Sanabria-Castro","year":"2017","journal-title":"Ann. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/bmc-2016-0029","article-title":"Alzheimer\u2019s disease as an inflammatory disease","volume":"8","author":"Bol\u00f3s","year":"2017","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.ejmech.2021.113397_bib13","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1021\/cr300009x","article-title":"Bioinorganic chemistry of alzheimer \u2019 s disease","volume":"112","author":"Kepp","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113397_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2021.113397_bib15","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2021.113397_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/03007990152673800","article-title":"A\u00a0new therapeutic target in Alzheimer\u2019s disease treatment: attention to butyrylcholinesterase","volume":"17","author":"Greig","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2021.113397_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2018.1476494","article-title":"A\u00a0patent review of butyrylcholinesterase inhibitors and reactivators 2010\u20132017","volume":"28","author":"Andrisano","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113397_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.ejmech.2021.113397_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.trci.2017.07.001","article-title":"Neuropsychiatric signs and symptoms of Alzheimer\u2019s disease: new treatment paradigms","volume":"3","author":"Lanct\u00f4t","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejmech.2021.113397_bib21","first-page":"1","article-title":"Behavioral and psychological symptoms of dementia","author":"Cerejeira","year":"2012","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2021.113397_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","article-title":"Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"127","author":"Lanari","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejmech.2021.113397_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neurobiolaging.2005.06.003","article-title":"Involvement of the GABAergic system in depressive symptoms of Alzheimer\u2019s disease","volume":"27","author":"Garcia-Alloza","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2021.113397_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-014-0217-5","article-title":"Serotonergic therapies for cognitive symptoms in alzheimer\u2019s disease: rationale and current status","volume":"74","author":"Ramirez","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113397_bib25","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.2174\/1381612821666150914121149","article-title":"Treatment options in Alzheimer\u2019s disease: the GABA story","volume":"21","author":"Solas","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113397_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2016.00031","article-title":"Implications of GABAergic neurotransmission in Alzheimer\u2019s disease","volume":"8","author":"Li","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms18081813","article-title":"Towards a better understanding of GABAergic remodeling in alzheimer\u2019s disease","volume":"18","author":"Govindpani","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/alz.12088","article-title":"GABAergic dysfunction in excitatory and inhibitory (E\/I) imbalance drives the pathogenesis of Alzheimer\u2019s disease","volume":"16","author":"Bi","year":"2020","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.ejmech.2021.113397_bib29","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.2174\/0929867321666140601202158","article-title":"GABA system as a target for new drugs","volume":"21","author":"Kowalczyk","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3892\/etm.2015.2577","article-title":"\u03b3-aminobutyric acid transporter-1 is involved in anxiety-like behaviors and cognitive function in knockout mice","volume":"10","author":"Gong","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2021.113397_bib31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijbiomac.2020.04.126","article-title":"\u03b3-Aminobutyric acid transporters as relevant biological target: their function, structure, inhibitors and role in the therapy of different diseases","volume":"158","author":"\u0141\u0105tka","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.113397_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0197-0186(95)00158-1","article-title":"GABA transporter heterogeneity: pharmacology and cellular localization","volume":"29","author":"Borden","year":"1996","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2021.113397_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainresrev.2004.03.003","article-title":"GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications","volume":"45","author":"Conti","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113397_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-005-0017-9","article-title":"GAT1 and GAT3 expression are differently localized in the human epileptogenic hippocampus","volume":"111","author":"Lee","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2021.113397_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.113397_bib36","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1523\/JNEUROSCI.15-11-07734.1995","article-title":"GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex","volume":"15","author":"Minelli","year":"1995","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib37","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1523\/JNEUROSCI.16-19-06255.1996","article-title":"GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex","volume":"16","author":"Minelli","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00161","article-title":"Structure,function,and plasticity of GABA transporters","volume":"8","author":"Scimemi","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib39","article-title":"Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzhiemer\u2019 s disease model","volume":"5","author":"Wu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113397_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuroscience.2017.03.041","article-title":"Impaired expression of GABA transporters in the human Alzheimer\u2019s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus","volume":"351","author":"Fuhrer","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2021.113397_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0549-z","article-title":"Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia","volume":"13","author":"Hernandez-Rabaza","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2021.113397_bib42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bjp.0700957","article-title":"1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter","volume":"120","author":"Thomsen","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113397_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2014.06.024","article-title":"Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides","volume":"83","author":"Kowalczyk","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib44","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ejmech.2008.01.005","article-title":"Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4","volume":"43","author":"Kragler","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib45","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer\u2019s disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejmech.2021.113397_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2021.113397_bib47","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.3233\/JAD-190744","article-title":"Current and emerging pharmacological targets for the treatment of alzheimer\u2019s disease","volume":"72","author":"Morsy","year":"2019","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2021.113397_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/scientificamerican1191-68","article-title":"Amyloid protein and Alzheimer\u2019s disease","volume":"265","author":"Selkoe","year":"1991","journal-title":"Sci. Am."},{"key":"10.1016\/j.ejmech.2021.113397_bib49","first-page":"353","article-title":"The amyloid hypothesis of alzheimer \u2019s disease","volume":"297","author":"Hardy","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.ejmech.2021.113397_bib50","first-page":"1","article-title":"The \u03b2-secretase BACE1 in alzheimer\u2019s disease","author":"Hampel","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113397_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2018.00178","article-title":"Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"6","author":"Coimbra","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A\u00a0close look at BACE1 inhibitors for alzheimer\u2019s disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2021.113397_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.113397_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113397_bib55","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical alzheimer\u2019s disease","volume":"380","author":"Henley","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2020","key":"10.1016\/j.ejmech.2021.113397_bib56","article-title":"Alzheimer\u2019s disease drug development pipeline","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.ejmech.2021.113397_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for alzheimer\u2019s disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2021.113397_bib58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands - medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113397_bib59","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single Drug\u00a0: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A\u00a0perspective on multi - target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113397_bib61","doi-asserted-by":"crossref","first-page":"111572","DOI":"10.1016\/j.ejmech.2019.111572","article-title":"The chemistry toolbox of multitarget-directed ligands for Alzheimer\u2019s disease","volume":"181","author":"Mesiti","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2019.02.021","article-title":"Novel tacrine-tryptophan hybrids: multi-target directed ligands as potential treatment for Alzheimer\u2019s disease","volume":"168","author":"Chalupova","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib63","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1021\/acs.jmedchem.9b00937","article-title":"New dual small molecules for alzheimer\u2019s disease therapy combining histamine H3 receptor (H3R) antagonism and calcium channels blockade with additional cholinesterase inhibition","volume":"62","author":"Malek","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib64","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1021\/acs.jmedchem.9b00623","article-title":"Dual-acting cholinesterase-human cannabinoid receptor 2 ligands show pronounced neuroprotection in\u00a0vitro and overadditive and disease-modifying neuroprotective effects in\u00a0vivo","volume":"62","author":"Scheiner","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib65","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against alzheimer\u2019s disease: the design of donecopride","volume":"58","author":"Rochais","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib66","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1021\/acs.jmedchem.0c00528","article-title":"Centrally active multitarget anti-alzheimer agents derived from the antioxidant lead CR-6","volume":"63","author":"P\u00e9rez-Areales","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib67","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","article-title":"Tau-centric multitarget approach for alzheimer\u2019s disease: development of first-in-class dual glycogen synthase kinase 3\u03b2 and tau-aggregation inhibitors","volume":"61","author":"Gandini","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib68","doi-asserted-by":"crossref","first-page":"111916","DOI":"10.1016\/j.ejmech.2019.111916","article-title":"1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer\u2019s disease","volume":"187","author":"Wichur","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib69","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.bmc.2014.07.053","article-title":"Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with \u03b2-amyloid and tau anti-aggregating properties","volume":"22","author":"P\u00e9rez-Areales","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib70","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1016\/j.bmc.2018.08.007","article-title":"Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation","volume":"26","author":"Lv","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib71","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acsmedchemlett.9b00039","article-title":"Harnessing polypharmacology with medicinal chemistry","volume":"10","author":"Bolognesi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113397_bib73","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/acschemneuro.7b00461","article-title":"Design, synthesis, and biological evaluation of 1-Benzylamino-2-hydroxyalkyl derivatives as new potential disease-modifying multifunctional anti-alzheimer\u2019s agents","volume":"9","author":"Panek","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113397_bib74","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2174\/156802606778249801","article-title":"Structure-activity relationships of selective GABA uptake inhibitors","volume":"6","author":"Hog","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1054-3589(06)54011-6","article-title":"Structure-activity relationship and pharmacology of \u03b3-aminobutyric acid (GABA) transport inhibitors","volume":"54","author":"Clausen","year":"2006","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113397_bib76","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cmdc.201600599","article-title":"Development of highly potent GAT1 inhibitors: synthesis of nipecotic acid derivatives with N-arylalkynyl substituents","volume":"12","author":"Lutz","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113397_bib77","article-title":"Recent achievements and current directions of research into GABA uptake inhibitors","volume":"26","author":"Zar\u0119ba","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib78","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ijbiomac.2020.04.263","article-title":"Structure modeling of \u03b3-aminobutyric acid transporters \u2013 molecular basics of ligand selectivity","volume":"158","author":"\u0141\u0105tka","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.113397_bib79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0022-2836(84)90309-7","article-title":"Analysis of membrane and surface protein sequences with the hydrophobic moment plot","volume":"179","author":"Eisenberg","year":"1984","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113397_bib80","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1471-4159.2006.04260.x","article-title":"Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases \u03b2-cleavage of amyloid precursor protein and amyloid-\u03b2 production in\u00a0vivo","volume":"100","author":"Hussain","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113397_bib81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.bmcl.2007.12.028","article-title":"Potent memapsin 2 (\u03b2-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in\u00a0vivo evaluation","volume":"18","author":"Ghosh","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113397_bib82","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1021\/jm300069y","article-title":"Discovery of cyclic sulfone hydroxyethylamines as potent and selective \u03b2-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in\u00a0vivo reduction of amyloid \u03b2-peptides","volume":"55","author":"Rueeger","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1107\/S0907444911047251","article-title":"Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations","volume":"68","author":"Xu","year":"2012","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113397_bib84","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1021\/ja00752a081","article-title":"1-Hydroxybenzotriazole as a racemization-suppressing reagent for the incorporation of im-Benzyl-L-histidine into peptides","volume":"93","author":"Windridge","year":"1971","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113397_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113397_bib86","doi-asserted-by":"crossref","first-page":"112766","DOI":"10.1016\/j.ejmech.2020.112766","article-title":"Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors","volume":"208","author":"Meden","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib87","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ejmech.2018.07.033","article-title":"Multi-target-directed ligands for treating Alzheimer\u2019s disease: butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities","volume":"156","author":"Knez","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib88","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1021\/acs.jmedchem.6b00356","article-title":"Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by Structure-based virtual screening","volume":"59","author":"Dighe","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib89","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1021\/jm049379g","article-title":"Structure-based design of potent and selective cell-permeable inhibitors of human \u03b2-secretase (BACE-1)","volume":"47","author":"Stachel","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib90","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/cmdc.201200126","article-title":"Development of an (S)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] carba analogue inhibitor for murine \u03b3-aminobutyric acid transporter Type4","volume":"7","author":"Pabel","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113397_bib91","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/pro.5560020312","article-title":"Thioflavine T interaction with synthetic Alzheimer\u2019s disease \u03b2-amyloid peptides: detection of amyloid aggregation in solution","volume":"2","author":"Levine","year":"1993","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib92","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/jm0603015","article-title":"The physicochemical challenges of designing multiple ligands","volume":"49","author":"Morphy","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113397_bib93","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jcim.7b00190","article-title":"PlayMolecule ProteinPrepare: a web application for protein preparation for molecular dynamics simulations","volume":"57","author":"Mart\u00ednez-Rosell","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113397_bib94","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.3390\/ijms15035128","article-title":"Application of computational methods for the design of BACE-1 inhibitors: validation of in Silico modelling","volume":"15","author":"Bajda","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib95","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.3390\/ijms14035608","article-title":"Structure-based search for new inhibitors of cholinesterases","volume":"14","author":"Bajda","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib96","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acs.jcim.7b00650","article-title":"KDEEP: protein-ligand absolute binding affinity prediction via 3D-convolutional neural Networks","volume":"58","author":"Jim\u00e9nez","year":"2018","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113397_bib97","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/bioinformatics\/bty816","article-title":"Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server","volume":"35","author":"Vangone","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2021.113397_bib98","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1021\/acs.jctc.6b00049","article-title":"HTMD: high-throughput molecular dynamics for molecular discovery","volume":"12","author":"Doerr","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2021.113397_bib99","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113397_bib100","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.0014-2956.2001.02692.x","article-title":"Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization","volume":"269","author":"Nachon","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2021.113397_bib101","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/j.1742-4658.2012.08672.x","article-title":"Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure","volume":"279","author":"Brazzolotto","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.113397_bib102","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113397_bib103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113397_bib104","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113397_bib105","series-title":"MarvinSketch (Version 6.2.2)","year":"2014"},{"key":"10.1016\/j.ejmech.2021.113397_bib106","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113397_bib107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2005.06.053","article-title":"Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4","volume":"519","author":"Kragler","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113397_bib108","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cmdc.201500254","article-title":"Application of MS transport assays to the four human \u03b3-aminobutyric acid transporters","volume":"10","author":"Schmitt","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113397_bib109","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cmdc.200500038","article-title":"MS-binding assays: kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1","volume":"1","author":"Zepperitz","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113397_bib110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/molecules21040410","article-title":"Synthesis, molecular modelling and biological evaluation of novel heterodimeric, multiple ligands targeting cholinesterases and amyloid Beta","volume":"21","author":"Hebda","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113397_bib111","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1006\/abbi.1993.1311","article-title":"Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction","volume":"303","author":"Berridge","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.113397_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20143420","article-title":"The 1,3,5-triazine derivatives as innovative chemical family of 5-HT6 serotonin receptor agents with therapeutic perspectives for cognitive impairment","volume":"20","author":"Latacz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113397_bib113","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.3390\/molecules24244472","article-title":"Are the hydantoin-1,3,5-triazine 5-HT6R ligands a hope to a find new procognitive and anti-obesity drug? Considerations based on primary in\u00a0vivo assays and ADME-tox profile in\u00a0vitro","volume":"24","author":"Lubelska","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113397_bib114","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C8MD00313K","article-title":"Search for a 5-CT alternative. In\u00a0vitro and in\u00a0vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazole-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists","volume":"9","author":"Latacz","year":"2018","journal-title":"Medchemcomm"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:28:44Z","timestamp":1759328924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":114,"alternative-id":["S0223523421002464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113397","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of multifunctional anti-Alzheimer\u2019s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and \u03b3-aminobutyric acid transporters","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113397"}}